Home > Oncology > Escalating the ESCALADE trial: untreated diffuse large B-cell lymphoma

Escalating the ESCALADE trial: untreated diffuse large B-cell lymphoma

Presented By
Dr Laurie Sehn, University of British Columbia, Vancouver, Canada
Journal
Physician's Weekly
Conference
ASCO 2021
Trial
Phase 3, ESCALADE
The ESCALADE phase 3 trial is interrogating the clinical benefit of acalabrutinib in combination with standard chemotherapy for patients age 65 and younger with newly diagnosed with diffuse large B-cell lymphoma (DLBLC), the most common type of non-Hodgkin lymphoma. This ongoing trial was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held virtually 4-10 June, 2021 [1]. Medicom’s journalist spoke with principle investigator medical oncologist Dr Laurie Sehn (University of British Columbia, Vancouver, Canada). ESCALADE (NCT04529772) is a phase 3, placebo-controlled, randomized, global, double-blind study which ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on